The high frequency of hypermutated gliomas in our cohort, which is much higher than the 3.5% previously reported in glioblastoma [5], may suggest that the immunohistochemical loss of MMR proteins is useful to detect hypermutated tumors, as recently proposed by McCord et al. [8]. This evidence concerns the gene MRC1 and glioblastoma.